Skip to main content
OpenTrials
Completed

NCT Number: NCT03044301

Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)

The aim of this study is to evaluate the performance of the ZENEO needle free device in subcutaneous functioning limits (low performance limit and high performance limit) and for intramuscular injections.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • male or female healthy volunteers aged between 18 and 60 years,
  • affiliated to or covered by the French social security system,
  • BMI between ≥20 and ≤30 kg/m²
  • Patients without chronic medical or surgical illness
  • Patients with normal clinical examination at the screening visit,
  • Patients with normal blood pressure at the screening visit: systolic BP < 140 mmHg and diastolic BP < 90 mmHg, determined with the patient seated and resting for at least 5 minutes,
  • Patients within normal range values for the following laboratory tests (appendix I) unless the investigator considers an abnormality to be clinically irrelevant (to be documented and agreed with the sponsor before inclusion) within 1 month prior to the start of the study (only for MRI sub study volunteers),
  • Absence of cannabis, opiate, cocaine, amphetamine history (only for MRI sub study volunteers)

Exclusion criteria

  • history of drug abuse
  • history of hypersensitivity (disease or drug)
  • treatment with platelet inhibiting drugs within one week before inclusion
  • treatment with anticoagulant within four weeks before inclusion
  • subject likely to take any medication during the study
  • contra-indication to MRI: metallic intra-corporeal devices, claustrophobia
  • prior participation to other interventional clinical research within 3 months
  • in custody due to administrative or legal decision or under tutelage or being admitted in a sanitary or social institution.

Treatment and study plan

Intramuscular ZENEO® injection

Combination Product

Sodium Chloride (0.9 %)

Subcutaneous high ZENEO® injection

Combination Product

Sodium Chloride (0.9 %)

Subcutaneous low ZENEO® injection

Combination Product

Sodium Chloride (0.9 %)

Primary outcomes

  1. depth of the injection by MRI

    Time frame: 5 minutes after the injection

Sponsors and collaborators

Lead sponsor

Crossject

Industry

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Feb 7, 2017
Registry last updated
Feb 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.